Please enable JS

ARTICLES & TESTIMONIALS

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

GHLF Releases User’s Guide to the Healthcare System

Mar 30// GHLF in the news

GHLF has just released a User’s Guide to the Healthcare System. Included are explanations of common insurance barriers, tools for communicating with your provider’s office, information on how patients can become advocates, and more. Learn more below: https://www.everydayhealth.com/public-health/users-guide-healthcare-system-launches-today/ https://thedoctorweighsin.com/the-modern-patient-needs-to-be-an-expert-insurance-navigator/

READ MORE

50 State Network Director of Advocacy Steve Marmaras interviewed on Alaska Radio

Jan 05// GHLF in the news

Global Healthy Living Foundation’s Director of State and National Advocacy, Stephen Marmaras, recently was interviewed on the radio in Alaska to discuss recent biosimilar legislation and its implications for Alaskans.

READ MORE

Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions

Jul 18// GHLF in the news

The best-selling drugs Humira and Enbrel have a lot in common. They both use biotechnology to treat rheumatoid arthritis, psoriasis and other autoimmune diseases. And they come with giant price tags approaching $50,000 a year.

READ MORE

FDA advisory committee unanimously recommends approval of biosimilar to Enbrel – Perspective by Seth Ginsberg

Jul 15// GHLF in the news

The overall aim of biosimilar is to help contribute toward the reduction of cost for patients.

READ MORE

Biosimilar Confidence: Patient Perspectives on a New Medication Class – Seth Ginsberg

Jul 15// GHLF in the news

Imagine you’ve been living with rheumatoid arthritis for more than ten years.

READ MORE

Editorial: CreakyJoints Urges Uninterrupted Supply of Biosimilars

Feb 11// GHLF in the news

The existence of CT-P13, a biosimilar version of infliximab (Remsima), and its recommended approval on Tuesday by the FDA Arthritis Advisory Committee, is reason to celebrate.

READ MORE

KFRU-AM interview with Stephen Marmaras

Jan 22// GHLF in the news

Director, State and National Advocacy Stephen Marmaras speaks with David Lile on Columbia Morning on House Bill 1366

READ MORE

The FDA Introduces Naming Conventions for Biosimilars

Sep 02// GHLF in the news

Patient advocacy groups are praising the FDA for releasing a draft guidance that outlines the FDA’s proposed guidelines for naming biologics and biosimilars.

READ MORE

Maligned FDA Deserves Standing Ovation

Sep 02// GHLF in the news

Oftentimes, we forget how valuable our FDA is because we are used to only seeing the sensational critiques in the media: unwarranted drug approvals, inadequate surveillance, negligent public alerts or inappropriate industry influence.

READ MORE

5 reasons biosimilars must have distinguishable names

Jul 27// GHLF in the news

If you ask patients with severe chronic diseases, such as those with rheumatoid arthritis, cancer, or multiple sclerosis, what they believe is the most important factor in achieving a positive outcome for their condition or disease, the vast majority will say it’s the relationship they have with their physician and treatment team.

READ MORE